Why is the NIB (ASX:NHF) share price sliding 7% today?

JP Morgan is now bearish on NIB and reckons further downside is imminent.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Downward red arrow with business man sliding down it signifying falling asx share price.

Image source: Getty Images

Key points

  • JP Morgan downgraded NIB to underweight today
  • The broker slashed its price target by 12% to $6.10
  • The firm is cautious on the Australian health insurance sector over the medium to long-term
  • Analysts at the firm like Medibank as a better alternative
  • In the last 12 months the NIB share price has climbed more than 11%

Shares in private health insurer NIB Holdings Limited (ASX: NHF) are plunging more than 7% from the open today and now trade at $6.16 apiece.

Investors are selling the NIB share price today following a broker downgrade from investment bank JP Morgan.

In a note to clients, the broker deconstructs why NIB has fallen out of the limelight, and why it urges its clients to sell the insurer. Let's take a look.

Why's the NIB share price plunging today?

In the absence of any market-sensitive information from the company's camp today, it could be that JP Morgan slashed its price target for NIB by 12% to $6.10.

In doing so, it also assigned an underweight recommendation on the stock, downgrading the insurer from a previous neutral rating.

The broker reckons that insures such as NIB and Medibank Private Ltd (ASX: MPL) have benefitted tremendously from a slowdown in COVID-19 health claims in the short term.

However, it also notes that NIB has made promises that policyholders will see benefits returned to them, which poses a risk to long-term profits.

The broker isn't so rosy on the outlook of the Australian health insurance sector over the medium to long-term, noting widening capital requirements, lower rate increases and headwinds to profits in some business lines.

Specifically, the investment bank alludes to NIB's Australian Residents Health Insurance unit that appears to be struggling based on the numbers.

JP Morgan reckons that NIB will overreach its margin targets in this segment once again, especially due to its stance on retaining COVID-19 benefits for shareholders.

Analysts at the firm like Medibank as a better alternative, although the team also downgraded its view on NIB's rival to underweight as well today.

Shares have faltered after the broker released its scathing cross-examination on NIB, and are now trading at their lowest level in almost 6 months.

As seen on the chart below, both shares have tracked each other fairly closely over the last 12 months, with the exception of NIB's breakout-correction phase in August last year.

TradingView Chart

Hence, it appears we might be at a crossroads between the pair and the next course of direction in their share prices.

NIB share price snapshot

In the last 12 months, the NIB share price has climbed more than 11%. Since January 1 this year however, it has slipped well into the red and is 12% down.

Not only that, but in the last week of trading, shares have fallen another 6% amid a market-wide selloff that's been in situ since December last year.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man looking at his laptop and thinking.
Broker Notes

What is Morgans saying about A2 Milk and these ASX shares?

Let's see what the broker is saying about these names.

Read more »

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Broker Notes

What does this broker have to say about Cleanaway Waste Management and Capstone Copper shares?

These shares have 20% to 30% upside.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 79%

A leading broker forecasts more outsized gains from this fast-rising ASX gold stock. But why?

Read more »

A person working on a computer holds a lightbulb that is connected to the network and shining brightly.
Broker Notes

Origin Energy shares: Experts argue the case to buy, hold, and sell

Three experts present three different ratings.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

What is Bell Potter saying about A2 Milk shares after the selloff?

Is this a buy, hold, or sell after Monday's weakness? Let's find out.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Broker Notes

Forget CBA shares and buy this ASX 200 stock: Shaw & Partners

Let's see what the broker is saying about these stocks.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on CBA and Woodside shares

A top analyst foresees mounting headwinds for CBA and Woodside shares.

Read more »